The allergy diagnostics and therapeutics market was valued at USD 40.45 Billion in 2025, driven by rising allergy prevalence worldwide. The market is anticipated to grow at a CAGR of 8.40% during the forecast period of 2026-2035, with values likely to reach USD 90.62 Billion by 2035.
Latest News on the Allergy Diagnostics and Therapeutics Market (2026)
April 2026: FDA Grants Fast Track to Kymera's Oral STAT6 Degrader
The FDA granted fast track designation on 24 April to Kymera Therapeutics' KT-621, a first-in-class once-daily oral STAT6 degrader, for moderate to severe eosinophilic asthma, adding to an existing designation in atopic dermatitis. Phase 1b BroADen data showed reductions in fractional exhaled nitric oxide and improved Asthma Control Questionnaire scores, positioning the candidate against injectable IL-4 and IL-13 biologics, Healio reported.March 2026: AAAAI Highlights Barzolvolimab and Dupilumab Urticaria Wins
The 2026 American Academy of Allergy, Asthma and Immunology meeting in Philadelphia showcased Celldex Therapeutics' barzolvolimab Phase 2 data showing 70.5% of chronic spontaneous urticaria patients achieving well-controlled disease at 52 weeks, alongside dupilumab efficacy across CSU subpopulations. GLP-1 agonists were also linked to lower asthma exacerbation risk in non-diabetic patients, MedCentral reported.Market Size & Forecast
- Market Size in 2025: USD 40.45 Billion
- Projected Market Size in 2035: USD 90.62 Billion
- Compound Annual Growth Rate (CAGR) of 2026 to 2035: 8.40%
Market Segmentation
The allergy diagnostics & therapeutics market can be divided on the basis of segments like product, allergen type, end-use, diagnostic tests, and drug class.The industry can be broadly categorised on the basis of product into:
- Instruments
- Consumables
- Services
The industry can be categorised on the basis of allergen type into:
- Food
- Inhaled
- Drug
- Others
The industry can be divided based on end-uses into:
- Diagnostics labs
- Hospitals
- Academic Research Institutes
The industry can be divided on the basis of diagnostic tests as:
- In-Vivo
- Skin Prick Test
- Intradermal
- Patch Test
- In-Vitro
The industry can be segmented based on drug class as:
- Antihistamines
- Decongestants
- Corticosteroids
- Mast Cell Stabilizers
- Leukotriene Inhibitors
- Nasal Anticholinergics
- Immunomodulators
- Autoinjectable Epinephrine
- Immunotherapy
The industry can be segmented based on region as:
- North America
- Europe
- Asia Pacific
- Latin America
- Middle East and Africa
Market Analysis
The growth of the allergy diagnostics & therapeutics industry is expected to be driven by a number of factors, such as the high incidence and high economic burden of allergic diseases, increased healthcare spending, and increased access to medical insurance in the United States. Within allergy testing, factors such as widespread availability and high consumption of assay kits are expected to drive the development of this segment in the following years. The category of inhaled allergens is projected to represent the largest share of the market for allergy diagnostics in the forecast period. Increasing environmental pollution is one of the main factors driving the market growth. Growing investments, rising research activities, and increasing acceptance from the United States for allergy treatment via medical insurance are the key factors accelerating the market growth.Competitive Landscape
The report presents a detailed analysis of the following key players in the global allergy diagnostics & therapeutics market, looking into their capacity, competitive landscape, and latest developments like capacity expansions, plant turnarounds, and mergers and acquisitions:- GlaxoSmithKline plc
- Stallergenes Greer Ltd
- Hitachi Chemical Co., Ltd
- Omega Diagnostics Group PLC
- bioMérieux SA
- Thermo Fisher Scientific Inc.
- Siemens Healthcare GmbH
- Others
Table of Contents
1 Preface2 Report Coverage - Key Segmentation and Scope4 Key Assumptions7 Opportunities and Challenges in the Market15 Value Chain Analysis
3 Report Description
5 Executive Summary
6 Snapshot
8 Global Allergy Diagnostics and Therapeutics Market Analysis
9 North America Allergy Diagnostics and Therapeutics Market Analysis
10 Europe Allergy Diagnostics and Therapeutics Market Analysis
11 Asia Pacific Allergy Diagnostics and Therapeutics Market Analysis
12 Latin America Allergy Diagnostics and Therapeutics Market Analysis
13 Middle East and Africa Allergy Diagnostics and Therapeutics Market Analysis
14 Market Dynamics
16 Competitive Landscape
Companies Mentioned
- GlaxoSmithKline plc
- Stallergenes Greer Ltd
- Hitachi Chemical Co., Ltd
- Omega Diagnostics Group PLC
- bioMérieux SA
- Thermo Fisher Scientific Inc.
- Siemens Healthcare GmbH
- Others
